Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma

National Medical Journal of China

Volumn 92, Issue 13, 2012, Pages 889-893

  Luo, Xiao Ning ^a   Lu, Li Gong ^a   Shao, Pei Jian ^a   Hu, Bao Shan ^a   Li, Yong ^a   Yu, Xian Yi ^a   He, Xu ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Carcinoma, hepatocellular; Drug eruptions; Sorafenib

Indexed keywords

SORAFENIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE CONTROL RATE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; HAND FOOD SKIN REACTION; HAZARD RATIO; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PATIENT MONITORING; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN MANIFESTATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DRUG ERUPTIONS; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84868291770     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.13.007     Document Type: Article

References (22)

1. Kong H H, Cowen E W, Azad N S, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol, 2007, 56: 171-172.
2. Chung N M, Gutierrez M, Turner M L. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol, 2006, 142: 1510-1511.
3. Strumberg D, Clark J W, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 2007, 12: 426-437.
4. Yang C H, Lin W C, Chuang C K, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinas einhibitor therapy. Br J Dermatol, 2008, 158: 592-596.
5. Azad N S, Aragon-Ching J B, Dahut W L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res, 2009, 15: 1411-1416.
6. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol, 2008, 103: 914-921.
7. Vogl T J, Zangos S, Balzer J O, et al. Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results. Rofo, 2007, 179: 1113-1126.
8. Varela M, Real M I, Burrel M, et al. Chemoembolization of hepatocellularcarcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol, 2007, 46: 474-481.
9. Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45: 228-247.
10. Llovet J M, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359: 378-390.
11. Cheng A L, Kang Y K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10: 25-34.
12. 2010, 15: 352-354.
13. 2008, 18: 135-138.
14. Chu D, Lacouture M E, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol, 2008, 47: 176-186.
15. Sheen Y S, Huang C L, Chu C Y. Eccrine squamous syringometaplasia associated with sunitinib therapy. J Eur Acad Dermatol Venereol, 2007, 21: 1136-1137.
16. Suwattee P, Chow S, Berg B C, et al. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol, 2008, 144: 123-125.
17. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer, 2006, 42: 548-556.
18. Robert C, Soria J C, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol, 2005, 6: 491-500.
19. Yang C H, Lin W C, Chuang C K, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol, 2008, 158: 592-596.
20. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist, 2011, 15: 85-92.
21. 2010, 90: 2187-2192.
22. 2010, 22: 466-468.